【與漢康讀懂腫瘤免疫新藥的抗癌革命】由漢康生技企劃製作

如果技術決定了一家公司能不能開始，那麼什麼決定了它能不能走到最後？
當許多人認為專利只是為了「防拷貝」，為什麼在生技產業，IP 卻是決定你能否上桌談判的入場券？
當 HCB101 接連在 2025 年與 2026 年拿下美國與日本兩大高門檻專利，這背後隱藏了什麼樣的商業變現與全球擴張底氣？
本集我們邀請到漢康生技商發長——叢越華博士，深入解析如何將看不見的智慧財產權，轉化為堅不可摧的商業壁壘與談判籌碼。

精彩內容：

• IP 的商業底層邏輯：為什麼專利不只是防守工具，更是參與全球生技賽局的「入場券（Right to play）」與談判桌上的關鍵籌碼？

• 美日專利雙殺的意義：拿下 2025 年美國專利（黃金標準）與 2026 年日本專利（最嚴格的 CMC 壓力測試），如何為漢康打通進軍高階醫藥市場的任督二脈？

• 無形資產的強力變現：專利認可如何直接轉化為 1,000 萬美元的授權首付款與超過 2,000 萬美元的募資里程碑？

• 平臺型的專利護城河：從核心資產 HCB101 到後續的 HCB301、HCB206，漢康如何利用 FBDB 平臺，建立多維度（適應症、製程、營業秘密）的防禦陣地？

• 投資人必問的三大 IP 問題：沒有技術背景怎麼辦？商發長教你從「自由營運權（FTO）」、「專利佈局密度與廣度」、「競爭者版圖」精準評估公司的真實價值。

【About This Episode】
If technology determines whether a company can get started, what determines if it can go the distance?
While many perceive patents merely as defensive tools against imitation, why is Intellectual Property (IP) actually the ultimate ticket to play and a crucial bargaining chip in the biotech industry?
With HCB101 securing patents in both the U.S. (2025) and Japan (2026)—two of the world's most rigorous markets—what commercial leverage and global expansion strategies lie beneath the surface?
In this episode, Dr. Cong Yuehua, Chief Business Officer at HanchorBio, decodes how invisible intellectual property is transformed into an impenetrable economic moat and powerful negotiation leverage.

【Key Takeaways】
The Commercial Logic of IP: Why is IP not just a defensive shield, but a "right to play" and a vital bargaining chip in global biotech partnerships?
Conquering the U.S. and Japan Markets: How do the 2025 U.S. patent (the gold standard) and the 2026 Japan patent (a massive CMC stress test) pave the way for entering high-end pharmaceutical markets?
Monetizing Intangible Assets: How does patent validation directly translate into a $10 million licensing upfront payment and over $20 million in fundraising success?
Building a Platform-Level Moat: From the lead asset HCB101 to subsequent programs like HCB301 and HCB206, how does HanchorBio leverage its FBDB platform to create a multi-layered defense (covering formulation, manufacturing, and trade secrets)?
Three Must-Ask IP Questions for Investors: No technical background? Dr. Cong explains how to evaluate a company's true worth by asking about "Freedom to Operate (FTO)," "portfolio density and geographic coverage," and the "competitor landscape."


漢康生技官網：https://www.hanchorbio.com/
漢康生技LinkedIn：https://reurl.cc/7b19y9

本節目旨在透過科學導讀與商業邏輯分享，幫助聽眾理解生技產業趨勢與漢康生技之核心價值。所有臨床數據均以公司正式發布之公告為準，內容不構成任何形式之投資建議。以上內容為創辦人基於產業經驗對產品潛力的評估，不代表公司對未來股價或獲利的保證。